Core Viewpoint - The global largest caffeine supplier, Shiyao Innovation Pharmaceutical Co., Ltd., is preparing for an IPO on the Hong Kong Stock Exchange, marking a significant transition as the company shifts from its traditional caffeine business to innovative pharmaceuticals amid a leadership change within its parent company, Shiyao Group [2][9]. Group 1: Company Background and Business Transition - Shiyao Innovation, formerly known as Sinoway, has been a long-term supplier of caffeine to major brands like Coca-Cola and Red Bull, and is recognized as the world's largest producer of synthetic caffeine [3][4]. - The company has been diversifying its business since 2016, entering the health food sector and acquiring 100% of Shiyao Shengxue, becoming a leading producer of acarbose raw materials [3][6]. - Despite its historical revenue from functional raw materials and health foods, which constituted over 90% of total revenue, there has been a decline from 2.57 billion yuan in 2022 to 1.84 billion yuan in 2024 [6][8]. Group 2: Financial Performance and Challenges - The financial performance of Shiyao Innovation has been declining, with revenues dropping from 2.84 billion yuan in 2022 to 1.98 billion yuan in 2024, and a net profit decrease from 294 million yuan in 2022 to a loss of 304 million yuan in 2024 [8][6]. - The acquisition of Shiyao Shengxue has introduced a new biopharmaceutical platform, but the revenue contribution from biopharmaceutical products remains below 10%, with the acquired entity still operating at a significant loss [8][6]. Group 3: Leadership Transition - A notable leadership transition occurred as Cai Lei, the son of the founder Cai Dongchen, took over as CEO of Shiyao Group, indicating a shift to a second-generation leadership [9][12]. - Cai Lei's background in international research and sales is expected to enhance the company's global strategy, focusing on overseas collaborations and clinical advancements [11][12]. - The leadership change coincides with the company's IPO plans, adding a layer of family legacy to the transition [9][12].

Investment Rating - The report maintains a "Buy" rating for the company [2][8]. Core Insights - The company has shown a recovery in revenue growth in Q2 2025, with a year-on-year increase of 29.0% in Q2 revenue, reaching 580 million yuan, and a quarter-on-quarter increase of 22.4% [8]. - The biopharmaceutical segment has experienced strong growth, with new products like Enlansumab and Omabizumab expected to drive revenue after their approval in 2024 [8]. - The company has entered a collaboration agreement with Radiance Biopharma for the exclusive development and commercialization rights of SYS6005, with a total transaction value of up to 1.24 billion USD [8]. - The caffeine and raw materials segment continues to solidify its market position, with caffeine product sales increasing by 14% year-on-year in H1 2025 [8]. - The report projects revenue for 2025 to be 2.19 billion yuan, with a year-on-year growth rate of 10.5%, and forecasts a gradual return to profitability by 2026 [9][10]. Financial Data and Profit Forecast - Total revenue for 2025 is estimated at 2,190 million yuan, with a projected growth rate of 10.5% [6]. - The company is expected to achieve a net profit of -5 million yuan in 2025, with a gradual improvement to 63 million yuan in 2026 and 111 million yuan in 2027 [6][9]. - The gross margin is projected to improve from 38.2% in H1 2025 to 51.1% by 2027 [6]. Valuation - The report uses a Free Cash Flow to Firm (FCFF) model for valuation, estimating a target price of 79.61 yuan per share, indicating a potential upside of 47% from the closing price on August 25, 2025 [10][13]. - The Weighted Average Cost of Capital (WACC) is calculated at 8.24% [11]. Segment Analysis - The functional foods and raw materials segment is expected to contribute revenues of 19.3 billion yuan in 2025, with a stable growth rate of 5% [10]. - The biopharmaceutical segment is projected to see significant growth, contributing revenues of 2.0 billion yuan in 2025, with a year-on-year growth rate of 130% [10].